Parabilis Medicines (PBLS) director receives stock options for 20,215 shares at $20

Rhea-AI Filing Summary

Parabilis Medicines, Inc. director Richard Klausner reported a compensation-related stock option grant. He received options covering 20,215 shares of common stock at an exercise price of $20.00 per share, with no cash paid at grant.

The options vest and become exercisable in full on the earlier of June 9, 2027 or the date of the company’s next annual meeting of stockholders, as long as he continues serving through that date. Following this award, he holds stock options for 20,215 underlying shares in this filing, reflecting a routine equity incentive grant rather than an open-market purchase or sale.

Insights

Equity compensation analyst

Routine director option grant with standard vesting, no open-market trading.

Director Richard Klausner received a grant of stock options covering 20,215 shares of Parabilis Medicines common stock at an exercise price of $20.00 per share. The transaction is coded as a grant/award, which indicates equity compensation rather than a market transaction.

The options vest in full on the earlier of June 9, 2027 or the issuer’s next annual stockholder meeting, contingent on continued service. This aligns with typical director compensation structures and does not represent a buy or sell decision in the open market.

Because there are no related sales, exercises, or large position changes disclosed, the event appears administratively routine and unlikely to alter the overall investment view on PBLS by itself.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Klausner Richard

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,215	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 20,215 shares (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Key Figures

Option shares granted: 20,215 shares Exercise price: $20.00 per share Underlying common shares: 20,215 shares +2 more

5 metrics

Option shares granted 20,215 shares Stock Option (Right to Buy) grant to director

Exercise price $20.00 per share Stock option exercise price

Underlying common shares 20,215 shares Shares of common stock underlying options

Expiration date June 8, 2036 Option expiration

Shares following transaction 20,215 options Total options held from this grant after transaction

Key Terms

Stock Option (Right to Buy), exercise price, vest and become exercisable, annual meeting of stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 20.0000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"The shares underlying this option shall vest and become exercisable in full"

annual meeting of stockholders financial

"the date of the Issuer's next annual meeting of stockholders"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/12/2026 - 01:23 PM Accepted by SEC EDGAR 06/11/2026 - 04:43 PM Learn about SEC filing dates

FAQ

What did Parabilis Medicines (PBLS) director Richard Klausner report on this Form 4?

He reported receiving a stock option grant for 20,215 shares of Parabilis Medicines common stock. The options were issued as a compensation award, not through an open-market purchase or sale, and give him the right to buy shares at a fixed exercise price.

How many Parabilis Medicines (PBLS) shares are covered by Klausner’s new stock option grant?

The grant covers options for 20,215 underlying shares of Parabilis Medicines common stock. After this award, the Form 4 shows total options for 20,215 shares held from this transaction, reflecting a single new equity incentive grant to the director.

What is the exercise price and expiration date of Klausner’s PBLS stock options?

The options have an exercise price of $20.00 per share and expire on June 8, 2036. This means he can choose to buy Parabilis Medicines shares at $20.00 any time after vesting until the stated expiration date, subject to plan terms.

When do Richard Klausner’s Parabilis Medicines (PBLS) options vest?

The options vest and become exercisable in full on the earlier of June 9, 2027 or the date of Parabilis Medicines’ next annual meeting of stockholders. Vesting requires his continued service as of that vesting date, according to the Form 4 footnote.

Does this PBLS Form 4 show Klausner buying or selling shares in the market?

No, it shows a stock option grant coded as a grant or award, not open-market trades. He received options as compensation, giving the right to buy shares later, but no common stock was purchased or sold in this transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klausner Richard

(Last) (First) (Middle)

C/O PARABILIS MEDICINES, INC.

30 ACORN PARK DRIVE, 6TH FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02140

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Parabilis Medicines, Inc. [ PBLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$20	06/09/2026		A		20,215		(1)	06/08/2036	Common Stock	20,215	$0.00	20,215	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

	/s/ Teresa Jurgensen, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)